Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer | Zendy

Cora N. Sternberg | Zendy; Karim Fizazi | Zendy; Fred Saad | Zendy; Neal D. Shore | Zendy; Ugo De Giorgi | Zendy; David F. Penson | Zendy; Ubirajara Ferreira | Zendy; Eleni Efstathiou | Zendy; Katarzyna Madziarska | Zendy; Michael Kolinsky | Zendy; Daniel de Iracema Gomes Cubero | Zendy; Bettioerby | Zendy; Fabian Zohren | Zendy; Xun Lin | Zendy; Katharina Modelska | Zendy; Jennifer Sugg | Zendy; Joyce Steinberg | Zendy; Maha Hussain | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Author(s) -

Cora N. Sternberg,

Karim Fizazi,

Fred Saad,

Neal D. Shore,

Ugo De Giorgi,

David F. Penson,

Ubirajara Ferreira,

Eleni Efstathiou,

Katarzyna Madziarska,

Michael Kolinsky,

Daniel de Iracema Gomes Cubero,

Bettioerby,

Fabian Zohren,

Xun Lin,

Katharina Modelska,

Jennifer Sugg,

Joyce Steinberg,

Maha Hussain

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2003892

Subject(s) - enzalutamide , prostate cancer , medicine , oncology , androgen deprivation therapy , overall survival , castration , metastasis , cancer , androgen , prostate specific antigen , androgen receptor , hormone

Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy. Results from the final analysis of overall survival have not yet been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research